Dual Carbon Change May Shorten Drug Discovery Paths

Binghamton University chemists have uncovered a reaction pathway that can alter two neighboring carbon atoms in a single step, a finding that may shorten the synthetic routes used in drug discovery.

In a study reported by Binghamton News on July 28, 2026, researchers describe a mechanism that breaks a long-standing rule in organic chemistry. Carbon-halogen bonds are among the most common “handles” chemists add to molecules so they can control reactions. “They follow a simple rule: one handle, one substitution,” said Associate Professor of Chemistry Jennifer Hirschi. Typically the halogen is removed and replaced with one new group—a reaction taught in undergraduate courses.

The new work, published in the journal Science, outlines a method that uses a single handle to add different groups to two neighboring carbon atoms at once. Hirschi co-led the project with Patricia Musacchio, assistant professor of chemistry at the University at Buffalo. Mechanistic studies were carried out by Tamal Das, a postdoctoral researcher in Hirschi’s lab at Binghamton’s Innovative Technologies Complex. The National Institutes of Health funded the research.

Carbon atoms sit at the core of many pharmaceutical molecules. In drug discovery research, those molecules are usually built one reaction at a time. Creating two chemical changes in a single step may shorten the route to a target compound, Hirschi explained. That efficiency matters because each extra synthetic step can add time, cost, and material loss before a candidate ever reaches biological testing.

Could one-step dual carbon changes really shrink drug discovery timelines?

The development makes a practical possibility clearer: fewer sequential reactions between a starting material and a desired scaffold. Industry analyses still put traditional paths from discovery to approval at roughly 10 to 15 years, with thousands of compounds screened for each medicine that reaches patients. Any reliable way to collapse two carbon functionalizations into one step could trim early chemistry cycles and free teams to test more designs.

Expansion will depend on how widely the pathway works. Open questions include which molecular scaffolds tolerate the dual change, how selective the reaction is when many functional groups are present, and whether yields stay high enough for scale-up. Those are ordinary hurdles for a new mechanism, not reasons to dismiss it. Comparative data—step counts, yields, and purity against standard one-handle substitutions on the same targets—would help labs judge when to adopt the shortcut.

The same idea could travel beyond pharmaceuticals. Materials chemistry, agrochemicals, and academic total synthesis all lean on carbon–carbon and carbon–heteroatom construction. A general single-handle, two-site method would give those fields another lever for shorter routes.

For readers watching science move from bench to benefit, the signal is concrete. A Binghamton–Buffalo team has shown that a familiar halogen handle can do more work than textbooks assumed. What to watch next is whether other groups reproduce the pathway on drug-like molecules and report the step savings in real discovery campaigns—evidence that will turn a promising mechanism into everyday practice.

Source: Binghamton University News, “Research: A new mechanism may shorten the time involved in drug discovery,” July 28, 2026.